Literature DB >> 30880797

Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.

Katie Atkinson1.   

Abstract

The thrombopoietin receptor agonists, eltrombopag and romiplostim, are second-line agents used to treat chronic immune thrombocytopenia purpura (ITP) in adults and children. ITP is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, petechiae, wet purpura, or blood in the urine or stool. This article reviews ITP treatment for adult and pediatric patients, including the use of the oral agent eltrombopag and the injectible agent romiplostim, nursing considerations, and patient education.

Entities:  

Keywords:  TPO-RA agents; eltrombopag; immune thrombocytopenia purpura; romiplostim

Mesh:

Substances:

Year:  2019        PMID: 30880797     DOI: 10.1188/19.CJON.212-216

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  1 in total

1.  Romiplostim for management of refractory immune thrombocytopenic purpura in the immediate postpartum period.

Authors:  Ariana Patras; Reinaldo Figueroa; Amit P Singh; Ichchha Madan
Journal:  BMJ Case Rep       Date:  2020-05-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.